Insider · CIK 0001633639

Cline Darren S

Reports to the SEC for 7 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001633639

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-11	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+70K sh	—	—	70,000
2026-03-24	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45.9K sh	—	—	45,867
2026-01-09	XENEXenon Pharmaceuticals Inc. · Restricted Share UnitsA Award	Chief Commercial Officer	AAward	+20K sh	—	—	20,000
2026-01-09	XENEXenon Pharmaceuticals Inc. · Share Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+40K sh	—	—	40,000
2025-06-23	XENEXenon Pharmaceuticals Inc. · Share Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+186K sh	—	—	185,800
2025-06-05	PLRXPLIANT THERAPEUTICS, INC. · Common Stock (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2025-03-31	PYXSPyxis Oncology, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+37K sh	$0.98	+$36.2K	36,979
2024-06-13	PLRXPLIANT THERAPEUTICS, INC. · Common Stock (Right to Buy)A Award	Director	AAward	+26.8K sh	—	—	26,764
2024-03-26	PYXSPyxis Oncology, Inc.A Award	Director	AAward	+35.2K sh	—	—	251,405
2023-06-16	IPI Legacy Liquidation CoStock Option (right to buy)A Award	Director	AAward	+13.2K sh	—	—	13,222
2023-06-07	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+14K sh	—	—	14,000
2023-04-12	IPI Legacy Liquidation CoStock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,013
2023-03-24	PYXSPyxis Oncology, Inc.A Award	Director	AAward	+139K sh	—	—	216,186
2023-03-06	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2022-03-31	PYXSPyxis Oncology, Inc.A Award	Director	AAward	+66.8K sh	—	—	76,831
2021-12-08	PYXSPyxis Oncology, Inc.P Purchase	Director	PPurchase	+10K sh	$9.39	+$93.9K	10,000
2021-10-07	PYXSPyxis Oncology, Inc. · Stock Option (Right to buy)A Award	Director	AAward	+42.2K sh	—	—	42,191
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−106K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−98K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−22.1K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−54.2K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−5,556 sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−75K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−46.9K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	U.S. Chief Commercial Officer	DDisposition to Issuer	−177K sh	—	—	0
2021-03-02	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+46.9K sh	—	—	46,896
2021-03-02	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+75K sh	—	—	75,024
2021-02-22	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+46.9K sh	—	—	46,896
2021-02-22	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+75K sh	—	—	75,024
2020-06-10	STEMLINE THERAPEUTICS INCU Disposition from Tender	Director	UDisposition from Tender	−35.5K sh	—	—	0
2020-06-04	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+106K sh	—	—	106,320
2020-06-04	GW PHARMACEUTICALS PLCShare OptionsA Award	U.S. Chief Commercial Officer	AAward	+177K sh	—	—	177,180
2020-05-28	GW PHARMACEUTICALS PLCStock OptionsM Exercise/Conversion	U.S. Chief Commercial Officer	MExercise/Conversion	−7,356 sh	—	—	0
2020-05-28	GW PHARMACEUTICALS PLCM Exercise/Conversion	U.S. Chief Commercial Officer	MExercise/Conversion	+7,356 sh	$0.00	+$8.827	7,356
2020-05-28	GW PHARMACEUTICALS PLCF Tax Payment	U.S. Chief Commercial Officer	FTax Payment	+1,800 sh	$10.54	+$19K	5,556
2019-06-25	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+15K sh	—	—	35,468
2019-05-28	GW PHARMACEUTICALS PLCStock OptionsA Award	U.S. Chief Commercial Officer	AAward	+54.2K sh	—	—	54,192
2019-05-28	GW PHARMACEUTICALS PLCStock OptionsA Award	U.S. Chief Commercial Officer	AAward	+98K sh	—	—	98,040
2019-05-28	GW PHARMACEUTICALS PLCA Award	U.S. Chief Commercial Officer	AAward	+29.4K sh	$0.00	+$38.251	29,424
2018-11-29	Seagen Inc.S Sale	EVP, Commercial	SSale	−7,000 sh	$62.88	−$440K	72,556
2018-11-21	Seagen Inc.S Sale	EVP, Commercial	SSale	−4,167 sh	$56.68	−$236K	79,556
2018-08-30	Seagen Inc.Incentive Stock Option (right to buy)A Award	EVP, Commercial	AAward	+1,301 sh	—	—	1,301
2018-08-30	Seagen Inc.A Award	EVP, Commercial	AAward	+18.6K sh	—	—	83,723
2018-08-30	Seagen Inc.Non-Qualified Stock Option (right to buy)A Award	EVP, Commercial	AAward	+43K sh	—	—	42,984
2018-08-27	Seagen Inc.S Sale	EVP, Commercial	SSale	−4,784 sh	$74.23	−$355K	65,079
2018-06-21	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+20.5K sh	—	—	20,468
2018-06-12	Seagen Inc.Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP, Commercial	MExercise/Conversion	−8,000 sh	—	—	1,583
2018-06-12	Seagen Inc.Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP, Commercial	MExercise/Conversion	−926 sh	—	—	0
2018-06-12	Seagen Inc.Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP, Commercial	MExercise/Conversion	−892 sh	—	—	0
2018-06-12	Seagen Inc.Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP, Commercial	MExercise/Conversion	−268 sh	—	—	0

Recent filings

Accepted (ET)
Jun 124
Cline Darren S0001746473-26-000099
SEC(opens sec.gov)
Mar 254
Cline Darren S0001193125-26-124325
SEC(opens sec.gov)
Jan 94
Cline Darren S0001193125-26-009235
SEC(opens sec.gov)
Jun 244
Cline Darren S0000950170-25-089721
SEC(opens sec.gov)
Jun 94
Cline Darren S0001746473-25-000127
SEC(opens sec.gov)
Apr 24
Cline Darren S0000950170-25-048899
SEC(opens sec.gov)
Jun 174
Cline Darren S0001746473-24-000103
SEC(opens sec.gov)
Mar 284
Cline Darren S0000950170-24-038105
SEC(opens sec.gov)
Jun 204
Cline Darren S0001209191-23-038606
SEC(opens sec.gov)
Jun 84
Cline Darren S0001209191-23-035511
SEC(opens sec.gov)
Apr 144
Cline Darren S0001209191-23-024348
SEC(opens sec.gov)
Mar 284
Cline Darren S0001209191-23-021405
SEC(opens sec.gov)
Mar 84
Cline Darren S0001209191-23-017213
SEC(opens sec.gov)
Apr 44
Cline Darren S0001140361-22-012914
SEC(opens sec.gov)
Dec 94
Cline Darren S0000899243-21-047525
SEC(opens sec.gov)
Oct 124
Cline Darren S0001140361-21-034425
SEC(opens sec.gov)
May 74
Cline Darren S0000899243-21-018670
SEC(opens sec.gov)

Companies

Address

C/O PLIANT THERAPEUTICS, INC. 331 OYSTER POINT BOULEVARD

SOUTH SAN FRANCISCO, CA, 94080